Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

Presence of Novel Psychoactive Substances in Confirmed Negative Benzodiazepine Clinical Urine Specimens

SOFT-THIAFT 2026

Joint meeting between Society of Forensic Toxicologists and The International Association of Forensic Toxicologists

Chicago, IL, Sep 19-24, 2026

Poster presentation: Presence of Novel Psychoactive Substances in Confirmed Negative Benzodiazepine Clinical Urine Specimens

(abstract can be found on page 560 in abstract book: link above)

Authors: Yeomans NR, Neifeld JR, Pacana AL, Bland AA, Meli TM, Bartock SH

Medical Specialty: Prescription drug monitoring, Toxicology

Related content

On-Demand Webinar
The Growing Crisis of Novel Psychoactive Substances
Audio Podcast
Novel Psychoactive Substances (NPS): A Dangerous, Widespread Public Health Issue
Test FAQ
Novel Psychoactive Substances (NPS) Panel

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.